Toshiaki Iwase

Dr. Toshiaki Iwase

University of Texas MD Anderson Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
Toshiaki IwaseToshiaki Iwase
Toshiaki Iwase
Xiaoping WangXiaoping Wang
Xiaoping Wang
TSTushaar Vishal Shrimanker
Tushaar Vishal Shrimanker
MKMikhail Kolonin
Mikhail Kolonin
Naoto T UenoNaoto T Ueno
Naoto T Ueno

2 December 2015 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
Toshiaki IwaseToshiaki Iwase
Toshiaki Iwase
TSTakafumi Sangai
Takafumi Sangai
TNTakeshi Nagashima
Takeshi Nagashima
MSMasahiro Sakakibara
Masahiro Sakakibara
JSJunta Sakakibara
Junta Sakakibara
MMMasaru Miyazaki
Masaru Miyazaki
Obesity is known to decrease the efficacy of neoadjuvant chemotherapy ( NAC ) against breast cancer; however, the relationship between actual body composition and NAC outcomes remains unknown. Therefore, we determined the effect of body composition on NAC outcomes. A total of 172 advanced breast cancer patients who underwent surgery after NAC were retrospectively analyzed. Body composition parameters including abdominal circumference ( AC ), subcutaneous fat area ( SFA ), visceral fat area ( VFA ), and skeletal muscle area ( SMA ) were calculated using computed tomography volume‐analyzing software. VFA / SFA ratio was used to evaluate visceral obesity. The associations of body composition parameters with pathological complete remission ( pCR ) and survival were analyzed. AC , SFA , and VFA were significantly correlated with body mass index ( BMI ) (all P < 0.05; r = 0.82, r = 0.71, and r = 0.78, respectively). AC , SFA , and VFA increased significantly and SMA decreased significantly after menopause (all P < 0.05). VFA / SFA ratio increased significantly after menopause, even though BMI remained unchanged. Body composition parameters were not associated with pCR . Distant disease‐free survival ( DDFS ) was significantly worse in the high VFA group than in the low VFA group ( P < 0.05). Furthermore, in the high VFA group, postmenopausal patients had significantly shorter DDFS than premenopausal patients ( P < 0.05). VFA was independently associated with DDFS in the multivariate analysis ( P < 0.05). High visceral fat is associated with worse NAC outcomes in breast cancer patients, especially postmenopausal patients. Interventions targeting visceral fat accumulation will likely improve NAC outcomes.

16 December 2022 in Science Advances
Verified
Journal Article
Open access
Xiaoping WangXiaoping Wang
Xiaoping Wang
TSTakashi Semba
Takashi Semba
GMGaniraju C. Manyam
Ganiraju C. Manyam
JWJing Wang
Jing Wang
SSShan Shao
Shan Shao
Naoto T UenoNaoto T Ueno
Naoto T Ueno
Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087), an anti-EGFR antibody combined with neoadjuvant chemotherapy produced the highest pathological complete response rate ever reported in patients with IBC having triple-negative receptor status. We determined the molecular and immunological mechanisms behind this superior clinical outcome. Using novel humanized IBC mouse models, we discovered that EGFR-targeted therapy remodels the IBC TME by increasing cytotoxic T cells and reducing immunosuppressive regulatory T cells and M2 macrophages. These changes were due to diminishing immunosuppressive chemokine expression regulated by transcription factor EGR1. We also showed that induction of an immunoactive IBC TME by an anti-EGFR antibody improved the antitumor efficacy of an anti–PD-L1 antibody. Our findings lay the foundation for clinical trials evaluating EGFR-targeted therapy combined with immune checkpoint inhibitors in patients with cancer.

16 October 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
Toshiaki IwaseToshiaki Iwase
Toshiaki Iwase
TSTakafumi Sangai
Takafumi Sangai
HFHiroshi Fujimoto
Hiroshi Fujimoto
YSYuji Sawabe
Yuji Sawabe
Kazuyuki MatsushitaKazuyuki Matsushita
Kazuyuki Matsushita
MOMasayuki Ohtsuka
Masayuki Ohtsuka

28 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Toshiaki IwaseToshiaki Iwase
Toshiaki Iwase
KBKim R. M. Blenman
Kim R. M. Blenman
XLXiaotong Li
Xiaotong Li
EREmily Reisenbichler
Emily Reisenbichler
RSRobert Seitz
Robert Seitz
Naoto T UenoNaoto T Ueno
Naoto T Ueno
A precise predictive biomarker for TNBC response to immunochemotherapy is urgently needed. We previously established a 27-gene IO signature for TNBC derived from a previously established 101-gene model for classifying TNBC. Here we report a pilot study to assess the performance of a 27-gene IO signature in predicting the pCR of TNBC to preoperative immunochemotherapy. We obtained RNA sequencing data from the primary tumors of 55 patients with TNBC, who received neoadjuvant immunochemotherapy with the PD-L1 blocker durvalumab. We determined the power and accuracy in predicting pCR for the immunomodulatory (IM) subtype identified by the 101-gene model, the 27-gene IO signature, and PD-L1 expression by immunohistochemistry (IHC). The pCR rate was 45% (25/55). The odds ratios for pCR were as follows: IM subtype by 101-gene model, 3.14 (p = 0.054); 27-gene IO signature, 4.13 (p = 0.012); PD-L1 expression by IHC, 2.63 (p = 0.106); 27-gene IO signature in combination with PD-L1 expression by IHC, 6.53 (p = 0.003). The 27-gene IO signature has the potential to predict the pCR of primary TNBC to neoadjuvant immunochemotherapy. Further analysis in a large cohort is needed.

1 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Xiaoping WangXiaoping Wang
Xiaoping Wang
TSTakashi Semba
Takashi Semba
LPLan Phi
Lan Phi
SCSudpreeda Chainitikun
Sudpreeda Chainitikun
Toshiaki IwaseToshiaki Iwase
Toshiaki Iwase
Naoto T UenoNaoto T Ueno
Naoto T Ueno
Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2–4% of breast cancer cases are classified as IBC, but—owing to its high rate of metastasis and poor prognosis—8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical studies of targeting these pathways in IBC. We also discuss studies of crosstalk between several signaling pathways and the IBC tumor microenvironment.